Hideyoshi Harashima Selected Research

Blood Glucose (Blood Sugar)

1/2016	Liver-Specific Silencing of Lipin1 Reduces Fat Mass as Well as Hepatic Triglyceride Biosynthesis in Mice.
6/2015	Forkhead Box O6 (FoxO6) Depletion Attenuates Hepatic Gluconeogenesis and Protects against Fat-induced Glucose Disorder in Mice.
3/2014	Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideyoshi Harashima Research Topics

Disease

99	Neoplasms (Cancer) 05/2024 - 10/2005
17	Mitochondrial Diseases (Mitochondrial Disease) 04/2023 - 02/2007
9	Neoplasm Metastasis (Metastasis) 03/2024 - 09/2013
9	Renal Cell Carcinoma (Grawitz Tumor) 05/2022 - 01/2012
7	Bites and Stings (Sting) 03/2024 - 06/2014
7	Melanoma (Melanoma, Malignant) 03/2024 - 03/2011
7	Urinary Bladder Neoplasms (Bladder Cancer) 12/2018 - 03/2009
6	Body Weight (Weight, Body) 10/2021 - 08/2011
5	COVID-19 05/2024 - 10/2021
5	Fibrosis (Cirrhosis) 02/2024 - 03/2021
5	Type 2 Diabetes Mellitus (MODY) 03/2014 - 12/2003
4	Obesity 10/2021 - 03/2013
4	Infections 01/2021 - 01/2013
3	Brain Diseases (Brain Disorder) 01/2018 - 04/2014
3	Insulin Resistance 03/2016 - 06/2015
3	Carcinogenesis 06/2011 - 12/2006
2	Congenital Heart Defects (Congenital Heart Defect) 02/2024 - 07/2018
2	Hepatocellular Carcinoma (Hepatoma) 01/2024 - 10/2021
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2023 - 10/2021
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2023 - 01/2023
2	Communicable Diseases (Infectious Diseases) 01/2023 - 01/2022
2	Glaucoma 11/2022 - 03/2021
2	Cardiomyopathies (Cardiomyopathy) 01/2020 - 10/2018
2	Colitis 12/2018 - 07/2016
2	Lymphoma (Lymphomas) 03/2016 - 02/2015
2	Reperfusion Injury 12/2015 - 09/2015
2	Hypersensitivity (Allergy) 06/2011 - 05/2011
2	Tuberculosis (Tuberculoses) 06/2011 - 05/2011
2	Carcinoma (Carcinomatosis) 06/2011 - 03/2009

Drug/Important Bio-Agent (IBA)

39	Small Interfering RNA (siRNA)IBA 12/2023 - 05/2009
24	Liposomes (Liposome)IBA 01/2022 - 10/2005
22	Lipid NanoparticlesIBA 05/2024 - 06/2011
20	LipidsIBA 01/2023 - 10/2007
18	LigandsIBA 01/2022 - 11/2011
15	Peptides (Polypeptides)IBA 01/2019 - 10/2005
12	Messenger RNA (mRNA)IBA 05/2024 - 12/2003
12	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 03/2003
10	Proteins (Proteins, Gene)FDA Link 04/2015 - 12/2006
9	AntigensIBA 05/2024 - 05/2011
9	Mitochondrial DNA (mtDNA)IBA 04/2023 - 10/2008
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 09/2007
7	InterferonsIBA 03/2024 - 06/2014
6	Therapeutic UsesIBA 03/2024 - 06/2011
6	Nucleic AcidsIBA 01/2022 - 01/2010
5	RNA (Ribonucleic Acid)IBA 12/2023 - 01/2010
5	Matrix Metalloproteinases (MMPs)IBA 12/2016 - 05/2007
5	Tuberculin (PPD)IBA 06/2011 - 10/2007
4	Photosensitizing Agents (Photosensitizers)IBA 01/2023 - 01/2020
4	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2020 - 05/2009
4	octaarginineIBA 11/2019 - 03/2009
4	Hyaluronic Acid (Hyaluronan)IBA 10/2019 - 06/2015
4	CytokinesIBA 11/2017 - 05/2011
4	Insulin (Novolin)FDA Link 03/2016 - 12/2006
4	YSK05IBA 10/2015 - 06/2013
3	mRNA VaccinesIBA 05/2024 - 01/2023
3	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2023 - 01/2020
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020 - 12/2016
3	Vitamin E FDA LinkGeneric 01/2020 - 02/2015
3	Cell-Penetrating PeptidesIBA 01/2017 - 08/2012
3	bis(3',5')-cyclic diguanylic acidIBA 12/2016 - 06/2014
3	Blood Glucose (Blood Sugar)IBA 01/2016 - 03/2014
3	Interferon Type IIBA 10/2015 - 06/2014
3	Nucleotide AptamersIBA 08/2014 - 01/2012
3	Cell Wall SkeletonIBA 02/2014 - 06/2011
3	liposomal doxorubicin (Doxil)FDA Link 07/2013 - 02/2007
2	OligodeoxyribonucleotidesIBA 03/2024 - 03/2011
2	AntioxidantsIBA 10/2023 - 01/2020
2	Oxygen (Dioxygen)IBA 01/2023 - 10/2021
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 06/2014
2	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2022 - 10/2018
2	VaccinesIBA 01/2022 - 01/2022
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2021 - 09/2015
2	MidkineIBA 10/2021 - 01/2019
2	Sorafenib (BAY 43-9006)FDA Link 10/2021 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2021 - 11/2020
2	PorphyrinsIBA 01/2020 - 01/2020
2	OvalbuminIBA 12/2018 - 01/2017
2	Dextran SulfateIBA 12/2018 - 07/2016
2	Myristic Acid (Tetradecanoic Acid)IBA 12/2018 - 02/2015
2	Nanoparticle Drug Delivery SystemIBA 11/2017 - 12/2016
2	coenzyme Q10 (CoQ10)IBA 01/2017 - 09/2015
2	cyclic arginine-glycine-aspartic acid peptideIBA 01/2016 - 09/2015
2	Triglycerides (Triacylglycerol)IBA 01/2016 - 03/2014
2	Glucose (Dextrose)FDA LinkGeneric 06/2015 - 09/2013
2	Biomarkers (Surrogate Marker)IBA 08/2014 - 01/2012
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2014 - 02/2007
2	LeptinIBA 10/2013 - 03/2013

Therapy/Procedure

50	Therapeutics 03/2024 - 10/2005
26	Immunotherapy 05/2024 - 03/2009
5	Photochemotherapy (Photodynamic Therapy) 01/2023 - 08/2008
5	Transplantation 01/2022 - 09/2013
4	Intravenous Administration 01/2023 - 10/2007
3	Cell Transplantation 02/2024 - 01/2020
3	Drug Therapy (Chemotherapy) 02/2015 - 01/2014
2	Precision Medicine 01/2024 - 04/2016
2	Intravenous Injections 12/2023 - 01/2023
2	Cell- and Tissue-Based Therapy (Cell Therapy) 12/2023 - 11/2021
2	Injections 01/2022 - 01/2014
2	Lab-On-A-Chip Devices 10/2021 - 01/2017
2	Lasers (Laser) 01/2017 - 03/2009